The acquisition will also allow the Southborough, MA- headquartered Veristat to expand quality assurance and pharmacovigilance capabilities into Europe and extend its core service areas into public affairs, market access, supply chain and healthcare compliance.
Headquartered in Basel, SFL is a consultancy with affiliates in Austria, Germany and the UK: with services across a pharma product’s life science: regulatory affairs, quality assurance, pharmacovigilance, medical writing, market access, public affairs, supply chain and healthcare compliance.
Led by founder and CEO Shayesteh Fürst-Ladani, SFL provides strategic advice and operational support with in-house expertise for a broad range of product types including small molecules, biologics, drug-device combination products, medical devices, in vitro diagnostics (IVDs) and advanced therapy medicinal products (ATMPs).
The SFL team has experience across a range of therapeutic areas - including an expertise in the field of orphan diseases and oncology - as well as future healthcare solutions that combine drugs with artificial intelligence (AI), devices and diagnostics.
SFL is ‘deeply embedded’ in the EU, UK and Swiss healthcare ecosystem and thus offers an advantage for US-based companies seeking entry into European markets, according to the company. It can act as an Applicant for a Marketing Authorization Application (MAA) and as Marketing Authorization Holder (MAH) in Switzerland, the EU and the UK.
The two companies share competencies in the areas of regulatory affairs, strategic consulting and medical writing with complementary geographic focus. Overlaying Veristat’s world-class biometrics and clinical trial operations capabilities, the joining of the organizations creates 'a multi-services force around clinical research and development to successfully meet the goals of sponsors and clients with an interest in the European region.'
“With scientific advances increasing our understanding of complex therapeutic challenges, our clients increasingly seek a CRO partner with experience in addressing the intricate challenges in program design, clinical trial conduct, and the regulatory approval and commercialization process,” said Patrick Flanagan, CEO at Veristat.
“Adding SFL’s talented team and services to Veristat’s offering will unlock meaningful potential and strengthen our ability to positively influence the scientific progress, regulatory assessment and launch success for patients with difficult-to-treat diseases and conditions.”